With presence in four countries and over 20 years in the field of biologic drug discovery, Somata Genesis pioneers therapeutic applications that combine modern administration techniques with cells and cytokines to overcome disease and injury.

Headquartered in the UAE, with production bases in close proximity in India, Somata Genesis leverages progressive regulatory oversight and cost-effectiveness to deliver cutting-edge medical delivery technology. 

Somata Genesis, Inc. is also the first company to establish collaborative associations within the US health insurance sector and with OHRP oversight for Phase I clinical trial coverage of its MS NCT biologic Neutrojen M-150 under the provisions of the Right to Try Act 2018.

Somata Genesis Biotech Pvt. Ltd. leverages India’s cost-effective clinical research and diverse manufacturing pool to constantly improve its formulations and engage highly experienced Indian surgeons and scientists to develop and deliver clinical protocols achievable nowhere else in the world. At present, the company is building an all-in-one research and medical facility on the scenic west coast of India.

About the founder

Surjo Banerjee, founder of Somata Genesis, entered clinical research with a vision to overcome the most challenging areas of modern medicine where only symptomatic suppression exists. With a focus on cerebral issues rooted in insufficiency, Banerjee explored vascular links to neurological problems and later used his findings to develop methods to restore function in aging and impacted tissue and organs.